SCHEMBL3522648

SCHEMBL3522648

O=c1nc(-c2ccc3c(c2)OCO3)c2ccc3c(c2[nH]1)OCO3

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 1/20 0.51
TNKS O95271 1/20 0.45
PARP1 P09874 1/20 0.45
TNKS2 Q9H2K2 1/20 0.45
MAP2K4 P45985 4/20 0.44
MAPK1 P28482 2/20 0.44
MAPKAPK2 P49137 2/20 0.44
MAPKAPK3 Q16644 2/20 0.44
MAPK6 Q16659 2/20 0.44
CHEK1 O14757 1/20 0.44
AURKA O14965 1/20 0.44
DAPK3 O43293 1/20 0.44
JAK2 O60674 1/20 0.44
PRKD3 O94806 1/20 0.44
MAP4K4 O95819 1/20 0.44
PAK4 O96013 1/20 0.44
ABL1 P00519 1/20 0.44
NTRK1 P04629 1/20 0.44
LCK P06239 1/20 0.44
CSF1R P07333 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3519703 0.80 MAP2K4 (0.50) TNKSPARP1TNKS2MAP2K4MAPK1
SCHEMBL3525845 0.80 MAP2K4 (0.45) TNKSPARP1TNKS2MAP2K4MAPK1
SCHEMBL3519897 0.77 MAP2K4 (0.47) TNKSPARP1TNKS2MAP2K4MAPK1
SCHEMBL3522440 0.68 CLK4 (0.61) MAP2K4MAPK1MAPKAPK2MAPKAPK3MAPK6
SCHEMBL3523436 0.67 MAP2K4 (0.57) TNKSPARP1TNKS2MAP2K4MAPK1
SCHEMBL3523207 0.67 PDE3B (0.58) TNKSPARP1TNKS2KDM4EALDH1A1
SCHEMBL29118694 0.65 CTSL (0.56) TNKSPARP1TNKS2MAP2K4MAPK1
SCHEMBL20448985 0.65 DYRK1A (0.64) MAP2K4MAPK1MAPKAPK2MAPKAPK3MAPK6
SCHEMBL11384517 0.64 MEN1 (0.52) MAP2K4MAPK1MAPKAPK2MAPKAPK3MAPK6
SCHEMBL14578434 0.64 NPC1 (0.54) TNKSMAPK1CLK4ALOX5PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652006-B2 For therapy and prophylaxis of neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, for ameliorating neurodegenerative diseases EURO-CELTIQUE S.A. (LU) 2010-01-26 US disclosed